The new capital will accelerate the expansion of Immobazyme’s proprietary biologics platform and advance its therapeutics program as part of the company’s global growth strategy.
The new capital will accelerate the expansion of Immobazyme’s proprietary biologics platform and advance its therapeutics program as part of… Read More
The new capital will accelerate the expansion of Immobazyme’s proprietary biologics platform and advance its therapeutics program as part of the company’s global growth strategy.
OneBio Venture Studio, has secured a R20 million grant facility designed to accelerate the growth of high-impact biotechnology startups across the continent.
Deploying this capital marks a strategic intervention in the African venture landscape, where early-stage biotechnology often faces a structural funding vacuum. By providing non-dilutive capital, OneBio intends to bridge the high-risk “valley of death” that separates academic intellectual property from institutional investment readiness.
The facility will be utilised to dismantle the barriers between laboratory research and global markets through three key pillars:
OneBio Venture Studio remains committed to building a local biotech ecosystem that leverages local talent to solve global challenges. This grant facility reinforces OneBio’s role as a catalyst for biotech entrepreneurship in Africa, ensuring that the continent’s scientific intellectual property is fully realised.
This allocation will launch the new initiative, ‘Upscalator’, to support Danish and European early-stage startups with facilities, services, and expertise to support that novel biosolutions reach the market and can drive the green transition.
Prof Erick Strauss from Stellenbosch University’s Department of Biochemistry is leading one of two African project teams selected to participate in a global consortium to transform antibiotic discovery to counter the growing antimicrobial resistance (AMR) crisis.